Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Early-Stage Funding Gap Targeted By Two New U.K. Funds, Deepbridge Innovation Fund And Target Development Fund

This article was originally published in The Pink Sheet Daily

Executive Summary

Deepbridge Capital aims to raise £250 million to support early-stage research, recruits ex-GSK CEO Sykes to chair investment committee.

You may also be interested in...

U.K Tech Transfer Firm IP Group Raises $90 million To Support Early-Stage Portfolio Companies

IP Group raises funds to support academic spin-outs as VC funds and IPOs remain scarce

Imperial Innovations Raises £140 Million To Invest In University Spin-Outs

The AIM-listed tech transfer group will increase its early-stage investments in spin-outs from Imperial College and three other top UK universities

Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind

Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts